These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19262256)

  • 1. High-dose methotrexate: the rationale..
    Cheok MH; Evans WE; Kager L
    J Pediatr Hematol Oncol; 2009 Mar; 31(3):224-5. PubMed ID: 19262256
    [No Abstract]   [Full Text] [Related]  

  • 2. Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma.
    Hui KH; Chu HM; Fong PS; Cheng WTF; Lam TN
    J Clin Pharmacol; 2019 Apr; 59(4):566-577. PubMed ID: 30556906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate is lethal to rats. Why give it to children?
    Cole PD; Kamen BA
    Pediatr Hematol Oncol; 2000 Dec; 17(8):609-13. PubMed ID: 11127392
    [No Abstract]   [Full Text] [Related]  

  • 4. [Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma].
    Ridolfi L; Barisone E; Vivalda M; Vivenza C; Brach Del Prever A; Leone L; Miniero R
    Minerva Pediatr; 1996 May; 48(5):193-200. PubMed ID: 8926955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose methotrexate is effective in osteosarcoma so what is the problem?
    Cohen IJ
    J Pediatr Hematol Oncol; 2009 Dec; 31(12):892-4. PubMed ID: 19887958
    [No Abstract]   [Full Text] [Related]  

  • 6. Outpatient high-dose methotrexate: proceed with extreme caution, if at all.
    Womer RB
    Pediatr Blood Cancer; 2010 Dec; 55(7):1250-1. PubMed ID: 20981687
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma.
    Mir O; Ropert S; Goldwasser F
    Lancet Oncol; 2008 Dec; 9(12):1198. PubMed ID: 19038767
    [No Abstract]   [Full Text] [Related]  

  • 8. [Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
    Cwliklińska M; Balwierz W; Nowak J; Stanuch H
    Przegl Lek; 2006; 63(1):15-20. PubMed ID: 16892893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature.
    Bielack SS; Beron G; Winkler K
    Cancer; 1997 Aug; 80(3):516-8. PubMed ID: 9241087
    [No Abstract]   [Full Text] [Related]  

  • 10. High-dose methotrexate in fibroblastic osteosarcoma.
    Chowbay B; Siong KK
    Ann Pharmacother; 2001 Dec; 35(12):1669. PubMed ID: 11793640
    [No Abstract]   [Full Text] [Related]  

  • 11. The influence of 7-OH methotrexate metabolite on clinical relevance of methotrexate determination.
    Klapkova E; Kukacka J; Kotaska K; Suchanska I; Urinovska R; Prusa R
    Clin Lab; 2011; 57(7-8):599-606. PubMed ID: 21888024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective.
    Mahadeo KM; Santizo R; Baker L; Curry JO; Gorlick R; Levy AS
    Pediatr Blood Cancer; 2010 Dec; 55(7):1296-9. PubMed ID: 20949591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic.
    Evans WE; Pui CH; Relling MV
    Adv Exp Med Biol; 1999; 457():537-41. PubMed ID: 10500831
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
    Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
    J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Accidental shortening time of high dose methotrexate infusion: case report and literature review].
    Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A
    Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma.
    Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individualization of the dosage of high-dose methotrexate by assaying plasma concentration. Therapeutic value in osteogenic sarcoma].
    Delepine N; Desbois JC; Delepine G; Cornille H; Astier A; Alkallaf S
    Bull Cancer; 1989; 76(8):913-8. PubMed ID: 2620125
    [No Abstract]   [Full Text] [Related]  

  • 19. The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study.
    Bonda-Shkedi E; Arush MW; Kaplinsky C; Ash S; Goshen Y; Yaniv I; Cohen IJ
    J Pediatr Hematol Oncol; 2013 May; 35(4):271-5. PubMed ID: 23612378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal methotrexate-induced acute chorea.
    Necioğlu Orken D; Yldrmak Y; Kenangil G; Kandraloğlu N; Forta H; Celik M
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):57-8. PubMed ID: 19125090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.